Trial Profile
Characterization of Exposure From Topical Administration of [14C] Umeclidinium to Axilla or Palm of Healthy Male Subjects
Status:
Completed
Phase of Trial:
Phase I
Latest Information Update: 05 Sep 2023
Price :
$35
*
At a glance
- Drugs Umeclidinium (Primary)
- Indications Asthma; Chronic obstructive pulmonary disease; Hyperhidrosis
- Focus Pharmacokinetics
- Sponsors GlaxoSmithKline; GSK
- 07 Aug 2014 Status changed from recruiting to completed as reported by ClinicalTrials.gov record.
- 24 Jul 2014 Planned End Date changed from 1 Feb 2014 to 1 Jan 2015 as reported by ClinicalTrials.gov record.
- 24 Jul 2014 Planned primary completion date changed from 1 Feb 2014 to 1 Jan 2015 as reported by ClinicalTrials.gov record.